Luca Valenti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1873025/publications.pdf

Version: 2024-02-01

468 papers	47,045 citations	4370 86 h-index	2071 204 g-index
481 all docs	481 docs citations	481 times ranked	33273 citing authors

#	Article	IF	Citations
1	Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2023, 21, 1523-1532.e1.	2.4	31
2	Genetic variation inTERTmodifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. Gut, 2023, 72, 381-391.	6.1	19
3	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. Gut, 2022, 71, 382-390.	6.1	113
4	A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores. Clinical Gastroenterology and Hepatology, 2022, 20, 658-673.	2.4	55
5	Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Digestive and Liver Disease, 2022, 54, 154-163.	0.4	15
6	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: comment. Internal and Emergency Medicine, 2022, 17, 299-302.	1.0	5
7	Is there an â€˜idealâ€™ diet for patients with NAFLD?. European Journal of Clinical Investigation, 2022, 52, e13659.	1.7	28
8	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	8.2	330
9	Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. International Journal of Obesity, 2022, 46, 486-493.	1.6	12
10	Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Realâ€Life Cohort Study. Hepatology Communications, 2022, 6, 867-877.	2.0	6
11	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in InÂVitro Models. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 759-788.	2.3	44
12	Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. Clinical and Molecular Hepatology, 2022, 28, 183-195.	4.5	6
13	PSD3 downregulation confers protection against fatty liver disease. Nature Metabolism, 2022, 4, 60-75.	5.1	15
14	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1-16.	1.1	15
15	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Digestive and Liver Disease, 2022, 54, 170-182.	0.4	12
16	Prognostic value of copeptin and midâ€regional proadrenomedullin in COVIDâ€19â€hospitalized patients. European Journal of Clinical Investigation, 2022, 52, e13753.	1.7	13
17	Clinical exome sequencing for diagnosing severe cryptogenic liver disease in adults: A case series. Liver International, 2022, 42, 864-870.	1.9	8
18	A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Alimentary Pharmacology and Therapeutics, 2022, 55, 234-243.	1.9	11

#	Article	IF	Citations
19	Genetics: A new clinical tool for the hepatologist. Liver International, 2022, 42, 724-726.	1.9	4
20	Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b. Science Translational Medicine, 2022, 14, eabh3831.	5.8	11
21	Rare ATG7 genetic variants predispose patients to severe fatty liver disease. Journal of Hepatology, 2022, 77, 596-606.	1.8	38
22	Global multi-stakeholder endorsement of the MAFLD definition. The Lancet Gastroenterology and Hepatology, 2022, 7, 388-390.	3.7	135
23	The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. Hepatology Communications, 2022, 6, 1213-1226.	2.0	9
24	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2008-e2020.	1.8	27
25	Preprocedural prophylaxis with blood products in patients with cirrhosis: Results from a survey of the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2022, 54, 1520-1526.	0.4	12
26	The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma. Frontiers in Endocrinology, 2022, 13, 869006.	1.5	6
27	Novel genes and sex differences in COVID-19 severity. Human Molecular Genetics, 2022, 31, 3789-3806.	1.4	38
28	Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives. , 2022, 1, 57-65.		7
29	LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover. Gut, 2021, 70, 180-193.	6.1	86
30	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. Journal of Hepatology, 2021, 74, 775-782.	1.8	193
31	PCSK9 rs11591147 R46L lossâ€ofâ€function variant protects against liver damage in individuals with NAFLD. Liver International, 2021, 41, 321-332.	1.9	26
32	Genetic insight into COVIDâ€19â€related liver injury. Liver International, 2021, 41, 227-229.	1.9	11
33	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. Journal of Autoimmunity, 2021, 116, 102560.	3.0	127
34	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. Journal of Hepatology, 2021, 74, 20-30.	1.8	77
35	Should individuals who have been cured of hepatitis C virus and their partners be allowed to donate blood?. Lancet Haematology,the, 2021, 8, e8-e10.	2.2	0
36	Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders. Journal of Clinical Medicine, 2021, 10, 423.	1.0	9

#	Article	IF	Citations
37	Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19. Journal of Autoimmunity, 2021, 117, 102595.	3.0	44
38	Adipocyte PHLPP2 inhibition prevents obesity-induced fatty liver. Nature Communications, 2021, 12, 1822.	5.8	17
39	The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. EBioMedicine, 2021, 65, 103249.	2.7	11
40	A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?. Cancers, 2021, 13, 1412.	1.7	26
41	Emergency Lung Transplantation after COVID-19: Immunopathological Insights on Two Affected Patients. Cells, 2021, 10, 611.	1.8	11
42	The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. Cancers, 2021, 13, 1783.	1.7	16
43	Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. Gastroenterology, 2021, 160, 1634-1646.e7.	0.6	82
44	A call to action for fatty liver disease. Liver International, 2021, 41, 1182-1185.	1.9	10
45	Reply to: â€œPolygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver diseaseâ€. Journal of Hepatology, 2021, 74, 1494-1496.	1.8	9
46	Natural history of NASH. Liver International, 2021, 41, 78-82.	1.9	16
47	Prognostic parameters of inâ€hospital mortality in COVIDâ€19 patientsâ€”An Italian experience. European Journal of Clinical Investigation, 2021, 51, e13629.	1.7	31
48	Current management of NAFLD/NASH. Liver International, 2021, 41, 89-94.	1.9	14
49	Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank. JHEP Reports, 2021, 3, 100262.	2.6	15
50	Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis. Science Translational Medicine, 2021, 13, .	5.8	49
51	Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. JHEP Reports, 2021, 3, 100284.	2.6	28
52	COVIDâ€19 and the liver: A 2021 update. Liver International, 2021, 41, 1988-1998.	1.9	34
53	Clinical Determinants of Disease Progression in Patients With Beta-Sarcoglycan Gene Mutations. Frontiers in Neurology, 2021, 12, 657949.	1.1	5
54	Feasibility and efficiency of European guidelines for NAFLD assessment in patients with type 2 diabetes: A prospective study. Diabetes Research and Clinical Practice, 2021, 177, 108882.	1.1	9

#	Article	IF	Citations
55	Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Seminars in Liver Disease, 2021, 41, 421-434.	1.8	55
56	NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. Liver International, 2021, 41, 2712-2719.	1.9	6
57	Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma. Nature Communications, 2021, 12, 4878.	5.8	12
58	To Be or Not to Be: The Quest for Patatinâ€Like Phospholipase Domain Containing 3 p.I148M Function. Hepatology, 2021, 74, 2942-2944.	3.6	1
59	Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. Journal of Hepatology, 2021, 75, 506-513.	1.8	40
60	Liver Field during Immunotherapy of Hepatocellular Carcinoma: Some Like It Hot. Gastroenterology, 2021, 161, 1065-1067.	0.6	1
61	Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update. Hepatology Communications, 2021, 5, 1824-1832.	2.0	37
62	Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008â€2019. Liver International, 2021, , .	1.9	7
63	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology, 2021, 75, 770-785.	1.8	149
64	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2021, 75, 786-794.	1.8	100
65	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. Journal of Clinical Investigation, 2021, 131, .	3.9	72
66	Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. Journal of Autoimmunity, 2021, 124, 102728.	3.0	5
67	Preface. Clinics in Liver Disease, 2021, 25, xiii-xiv.	1.0	0
68	Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. Molecular Metabolism, 2021, 53, 101275.	3.0	22
69	Genetic risk scores and personalization of care in fatty liver disease. Current Opinion in Pharmacology, 2021, 61, 6-11.	1.7	13
70	Red blood cell morphology in patients with COVID-19-related anaemia. Blood Transfusion, 2021, 19, 34-36.	0.3	33
71	SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan. Blood Transfusion, 2021, 19, 181-189.	0.3	68
72	Variants APOE (rs429358) and TM6SF2 (rs187429064) confer risk to hepatocellular carcinoma. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.2	0

#	Article	IF	Citations
73	Trends and risk factors of <scp>SARSâ€CoV</scp>â€2 infection in asymptomatic blood donors. Transfusion, 2021, 61, 3381-3389.	0.8	12
74	PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opinion on Therapeutic Targets, 2021, 25, 1033-1043.	1.5	22
75	A genetic hypothesis for burntâ€out steatohepatitis. Liver International, 2021, 41, 2816-2818.	1.9	8
76	FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. Clinical Gastroenterology and Hepatology, 2020, 18, 517-519.	2.4	12
77	Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. Hepatology, 2020, 72, 88-102.	3.6	76
78	Î²-Klotho gene variation is associated with liver damage in children with NAFLD. Journal of Hepatology, 2020, 72, 411-419.	1.8	48
79	Impact of natural neuromedinâ€B receptor variants on iron metabolism. American Journal of Hematology, 2020, 95, 167-177.	2.0	7
80	Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease. Cell Metabolism, 2020, 31, 35-45.	7.2	130
81	AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement. Digestive and Liver Disease, 2020, 52, 359-367.	0.4	9
82	Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. Cell Metabolism, 2020, 31, 406-421.e7.	7.2	141
83	Association of <scp>ABO</scp> blood group and secretor phenotype with severe <scp>COVID</scp>â€19. Transfusion, 2020, 60, 3067-3070.	0.8	32
84	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemporary Clinical Trials, 2020, 98, 106175.	0.8	71
85	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158765.	1.2	10
86	Hepatic Fatâ€"Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs. Hepatology, 2020, 72, 1912-1923.	3.6	48
87	MAFLD vs NAFLD: Let the contest begin!. Liver International, 2020, 40, 2079-2081.	1.9	34
88	Management of Acute Hepatitis B Virus Infection. Current Hepatology Reports, 2020, 19, 276-284.	0.4	0
89	Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9. American Journal of Pathology, 2020, 190, 2226-2236.	1.9	26
90	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2020, 115, 1289-1292.	0.2	9

#	Article	IF	Citations
91	A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification. Journal of Hepatology, 2020, 73, S13-S14.	1.8	4
92	Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinology, Diabetes and Metabolism, 2020, 3, e00179.	1.0	10
93	Genetic variants in the MTHFR are not associated with fatty liver disease. Liver International, 2020, 40, 1934-1940.	1.9	5
94	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. New England Journal of Medicine, 2020, 383, 1522-1534.	13.9	1,548
95	Red cellâ€"bound antibodies and transfusion requirements in hospitalized patients with COVID-19. Blood, 2020, 136, 766-768.	0.6	60
96	Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology. Hepatology, 2020, 72, 330-346.	3.6	75
97	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLARÂtrials. Journal of Hepatology, 2020, 73, 26-39.	1.8	290
98	Prevalence and 9â€yyear incidence of hepatitis E virus infection among North Italian blood donors: Estimated transfusion risk. Journal of Viral Hepatitis, 2020, 27, 858-861.	1.0	7
99	COVIDâ€19 and liver disease. Liver International, 2020, 40, 1278-1281.	1.9	252
100	Update on NAFLD genetics: From new variants to the clinic. Journal of Hepatology, 2020, 72, 1196-1209.	1.8	234
101	PNPLA3I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings. Liver International, 2020, 40, 1130-1141.	1.9	33
102	COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemia. Clinical Microbiology and Infection, 2020, 26, 1576-1578.	2.8	10
103	Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. EBioMedicine, 2020, 52, 102658.	2.7	71
104	Approach to the patient with chronic hepatitis B and decompensated cirrhosis. Liver International, 2020, 40, 22-26.	1.9	7
105	Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis. Journal of Hepatology, 2020, 73, 361-370.	1.8	24
106	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158, 1999-2014.e1.	0.6	1,840
107	Comparison of three therapeutic regimens for genotypeâ€3 hepatitis C virus infection in a large realâ€life multicentre cohort. Liver International, 2020, 40, 769-777.	1.9	15
108	Uncovering the genetics of cirrhosis: New plots for the usual suspects. Liver International, 2020, 40, 281-282.	1.9	6

#	Article	IF	Citations
109	Virtual genetic diagnosis for familial hypercholesterolemia powered by machine learning. European Journal of Preventive Cardiology, 2020, 27, 1639-1646.	0.8	37
110	Redefining fatty liver disease classification in 2020. Liver International, 2020, 40, 1016-1017.	1.9	43
111	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. Journal of Hepatology, 2020, 73, 593-602.	1.8	38
112	Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis. Cell Metabolism, 2020, 31, 969-986.e7.	7.2	117
113	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 2020, 73, 202-209.	1.8	2,171
114	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohortâ˜†. Journal of Hepatology, 2020, 73, 505-515.	1.8	279
115	Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut, 2020, 69, 1855-1866.	6.1	75
116	The Natural History of NAFLD: Environmental vs. Genetic Risk Factors. , 2020, , 129-145.		2
117	Lack of genetic evidence that fatty liver disease predisposesÂtoÂCOVID-19. Journal of Hepatology, 2020, 73, 709-711.	1.8	24
118	Genetics and Epigenetics in the Clinic: Precision Medicine in the Management of Fatty Liver Disease. Current Pharmaceutical Design, 2020, 26, 998-1009.	0.9	10
119	Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C). Antiviral Therapy, 2019, 24, 35-44.	0.6	12
120	Preliminary Evidences of Safety and Efficacy of Flavonoids- and Omega 3-Based Compound for Muscular Dystrophies Treatment: A Randomized Double-Blind Placebo Controlled Pilot Clinical Trial. Frontiers in Neurology, 2019, 10, 755.	1.1	19
121	The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. Scientific Reports, 2019, 9, 11585.	1.6	82
122	Whole exome sequencing for personalized hepatology: Expanding applications in adults and challenges. Journal of Hepatology, 2019, 71, 849-850.	1.8	5
123	Novel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease. International Journal of Environmental Research and Public Health, 2019, 16, 2755.	1.2	28
124	Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents. Digestive and Liver Disease, 2019, 51, 1586-1592.	0.4	34
125	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. Hepatology, 2019, 70, 1521-1530.	3.6	197
126	NAFLD in children: new genes, new diagnostic modalities and new drugs. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 517-530.	8.2	199

#	Article	IF	Citations
127	mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance. Nutrients, 2019, 11, 2597.	1.7	24
128	Liver International: Anticipating the future of hepatology worldwide. Liver International, 2019, 39, 1796-1797.	1.9	2
129	Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis, 2019, 282, 110-120.	0.4	68
130	Serum coding and nonâ€coding RNAs as biomarkers of NAFLD and fibrosis severity. Liver International, 2019, 39, 1742-1754.	1.9	51
131	Building mass to prevent non-alcoholic fatty liver disease?. Hepatobiliary Surgery and Nutrition, 2019, 8, 173-176.	0.7	3
132	PS-177-HSD17B13 rs72613567 TA is associated with a reduced risk for developing hepatocellular carcinoma in patients with alcohol-related cirrhosis. Journal of Hepatology, 2019, 70, e109-e110.	1.8	5
133	FXR rs35724 G>C variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver. Digestive and Liver Disease, 2019, 51, e26.	0.4	3
134	Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis. Metabolism: Clinical and Experimental, 2019, 96, 56-65.	1.5	38
135	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology, 2019, 70, 1913-1927.	3.6	226
136	PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. Journal of Lipid Research, 2019, 60, 1144-1153.	2.0	42
137	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Scientific Reports, 2019, 9, 3682.	1.6	85
138	Genetics of Nonalcoholic Fatty Liver Disease: A 2018 Update. Current Pharmaceutical Design, 2019, 24, 4566-4573.	0.9	30
139	Accuracy of imaging methods for steatohepatitis diagnosis in nonâ€alcoholic fatty liver disease patients: A systematic review. Liver International, 2019, 39, 1521-1534.	1.9	24
140	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2310-2319.e6.	2.4	66
141	Postâ€transplant metabolic syndrome in children: Know better to cure better. Pediatric Transplantation, 2019, 23, e13367.	0.5	0
142	Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. Molecular Metabolism, 2019, 22, 49-61.	3.0	140
143	Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease. Diabetes and Metabolism, 2019, 45, 480-487.	1.4	36
144	Beyond fat accumulation, NAFLD genetics converges on lipid droplet biology. Journal of Lipid Research, 2019, 60, 7-8.	2.0	6

#	Article	IF	Citations
145	Financial Compensation For Hepatologists in Different Practice Settings. Hepatology, 2019, 69, 2664-2671.	3.6	4
146	Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease. Liver International, 2019, 39, 250-256.	1.9	38
147	Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. World Journal of Gastroenterology, 2019, 25, 6094-6106.	1.4	14
148	Uncovering occult hepatitis B in blood donations: a tale of two worlds. Blood Transfusion, 2019, 17, 399-400.	0.3	0
149	Nonalcoholic Fatty Liver Disease in Children. Seminars in Liver Disease, 2018, 38, 001-013.	1.8	108
150	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. Journal of Hepatology, 2018, 69, 18-24.	1.8	98
151	The next wave of hepatitis C virus: The epidemic of intravenous drug use. Liver International, 2018, 38, 34-39.	1.9	26
152	Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. Journal of Internal Medicine, 2018, 283, 356-370.	2.7	256
153	Hepatic iron is the major determinant of serum ferritin in <scp>NAFLD</scp> patients. Liver International, 2018, 38, 164-173.	1.9	65
154	Acquired hepatocerebral degeneration (AHD): a peculiar neurological impairment in advanced chronic liver disease. Metabolic Brain Disease, 2018, 33, 347-352.	1.4	4
155	The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2018, 22, 109-119.	1.0	46
156	Genetics and epigenetics of NAFLD and NASH: Clinical impact. Journal of Hepatology, 2018, 68, 268-279.	1.8	670
157	NGM282: a step forward in the nonalcoholic steatohepatitis treatment landscape?. Hepatobiliary Surgery and Nutrition, 2018, 7, 484-486.	0.7	2
158	Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Science Translational Medicine, 2018, 10, .	5.8	151
159	FGF23 and Fetuin-A Interaction in the Liver and in the Circulation. International Journal of Biological Sciences, 2018, 14, 586-598.	2.6	15
160	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. Hepatology Communications, 2018, 2, 666-675.	2.0	38
161	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. Journal of Hepatology, 2018, 69, 1365-1370.	1.8	51
162	Down-regulation of hepatic MBOAT7 by hyperinsulinemia favors steatosis development. Journal of Hepatology, 2018, 68, S31.	1.8	2

#	Article	IF	Citations
163	Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis. Atherosclerosis, 2018, 268, 27-31.	0.4	19
164	Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research. World Journal of Hepatology, 2018, 10, 231-245.	0.8	18
165	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Digestive and Liver Disease, 2017, 49, 471-483.	0.4	254
166	Impact of hepatitis C virus therapy on metabolism and public health. Liver International, 2017, 37, 13-18.	1.9	27
167	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An ageâ€dependent risk profiling study. Liver International, 2017, 37, 1389-1396.	1.9	44
168	Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. Clinical Science, 2017, 131, 1301-1315.	1.8	64
169	Fibronectin Type III Domainâ€“Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2660-2669.	1.8	42
170	Mutant PNPLA3 I148M protein as pharmacological target for liver disease. Hepatology, 2017, 66, 1026-1028.	3.6	25
171	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Clinical Gastroenterology and Hepatology, 2017, 15, 1604-1611.e1.	2.4	146
172	Developing a relationship with a liver transplant program. Clinical Liver Disease, 2017, 9, 73-76.	1.0	0
173	HFE mutations and iron in hemodialysis patients. Hemodialysis International, 2017, 21, S47-S57.	0.4	4
174	Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis. Gastroenterology, 2017, 153, 1568-1580.e10.	0.6	25
175	The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis. Scientific Reports, 2017, 7, 9273.	1.6	25
176	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancer Medicine, 2017, 6, 1930-1940.	1.3	43
177	Editorial: new insights into the relationship between the intestine and nonâ€alcoholic fatty liverâ€”is â€œfatty gutâ€•involved in disease progression?. Alimentary Pharmacology and Therapeutics, 2017, 46, 377-378.	1.9	6
178	Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies. Journal of Hepatology, 2017, 66, S593.	1.8	7
179	Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy. Current Hepatology Reports, 2017, 16, 169-177.	0.4	3
180	myVCF: a desktop application for high-throughput mutations data management. Bioinformatics, 2017, 33, 3676-3678.	1.8	8

#	Article	IF	Citations
181	Interferon lambda 4 rs368234815 TT>Î´G variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology, 2017, 66, 1885-1893.	3.6	75
182	Iron overload induces hypogonadism in male mice via extrahypothalamic mechanisms. Molecular and Cellular Endocrinology, 2017, 454, 135-145.	1.6	16
183	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Scientific Reports, 2017, 7, 4492.	1.6	193
184	GNPAT p.D519G variant and iron metabolism during oral iron tolerance test. Hepatology, 2017, 65, 384-385.	3.6	5
185	S18-1APPLYING GENETIC INFORMATION ON HEPATOCELLULAR CARCINOMA SURVEILLANCE STRATEGIES â€“ ARE WE THERE YET?. Alcohol and Alcoholism, 2017, 52, i4-i30.	0.9	0
186	GNPAT rs11558492 is not a Major Modifier of Iron Status: Study of Italian Hemochromatosis Patients and Blood Donors. Annals of Hepatology, 2017, 16, 451-456.	0.6	12
187	A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2017, 18, 1534.	1.8	54
188	Telomeric zinc-finger associated protein (TZAP): a new player in telomere diseases?. Annals of Translational Medicine, 2017, 5, 472-472.	0.7	7
189	GNPAT rs11558492 is not a Major Modifier of Iron Status: Study of Italian Hemochromatosis Patients and Blood Donors. Annals of Hepatology, 2017, 16, 451-456.	0.6	10
190	Pathophysiology of Non Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2016, 17, 2082.	1.8	126
191	Telomeres, NAFLD and Chronic Liver Disease. International Journal of Molecular Sciences, 2016, 17, 383.	1.8	48
192	Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0162473.	1.1	41
193	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0163069.	1.1	63
194	Proprotein convertase 7 rs236918 associated with liver fibrosis in Italian patients with HFEâ€related hemochromatosis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1342-1348.	1.4	15
195	PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes. Inflammatory Bowel Diseases, 2016, 22, 134-140.	0.9	27
196	The rs2294918 E434K variant modulates patatinâ€like phospholipase domainâ€containing 3 expression and liver damage. Hepatology, 2016, 63, 787-798.	3.6	93
197	DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. Hepatology, 2016, 63, 418-427.	3.6	31
198	Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia. Journal of Clinical Lipidology, 2016, 10, 816-823.	0.6	31

#	Article	IF	Citations
199	Liver fat accumulation is associated with circulating PCSK9. Annals of Medicine, 2016, 48, 384-391.	1.5	119
200	Particulate matter phagocytosis induces tissue factor in differentiating macrophages. Journal of Applied Toxicology, 2016, 36, 151-160.	1.4	10
201	Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?. Liver International, 2016, 36, 1563-1579.	1.9	126
202	Regulation of retinolâ€binding protein 4 and retinol metabolism in fatty liver disease. Hepatology, 2016, 64, 1414-1416.	3.6	8
203	PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. Human Molecular Genetics, 2016, 25, ddw341.	1.4	86
204	Destined to develop NAFLD? The predictors of fatty liver from birth to adulthood. Journal of Hepatology, 2016, 65, 668-670.	1.8	18
205	Reply to â€œStatin treatment for non-alcoholic steatohepatitisâ€. Journal of Hepatology, 2016, 64, 242-243.	1.8	0
206	Reply. Hepatology, 2016, 63, 1052-1053.	3.6	0
207	Hepcidin resistance in dysmetabolic iron overload. Liver International, 2016, 36, 1540-1548.	1.9	36
208	The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development â€“ a potential therapeutic target?. Expert Review of Gastroenterology and Hepatology, 2016, 10, 229-242.	1.4	44
209	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 64, 682-690.	1.8	106
210	Universal screening for chronic hepatitis C virus. Liver International, 2016, 36, 62-66.	1.9	22
211	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology, 2016, 150, 1219-1230.e6.	0.6	506
212	Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10Âyears of follow-up. Atherosclerosis, 2016, 246, 208-213.	0.4	78
213	AISF position paper on liver disease and pregnancy. Digestive and Liver Disease, 2016, 48, 120-137.	0.4	32
214	A â€œsystems medicineâ€•approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2016, 48, 333-342.	0.4	56
215	Genetics of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2016, 65, 1026-1037.	1.5	84
216	Nutritional therapy for nonalcoholic fatty liver disease. Journal of Nutritional Biochemistry, 2016, 29, 1-11.	1.9	100

#	Article	IF	Citations
217	Role of the receptor tyrosine kinase MER in the development of fibrosis in NAFLD. Digestive and Liver Disease, 2015, 47, e225.	0.4	0
218	Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection. Annals of Internal Medicine, 2015, 163, 809-817.	2.0	79
219	High Fat Diet Subverts Hepatocellular Iron Uptake Determining Dysmetabolic Iron Overload. PLoS ONE, 2015, 10, e0116855.	1.1	47
220	Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. BioMed Research International, 2015, 2015, 1-10.	0.9	116
221	Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of Hepatology, 2015, 63, 705-712.	1.8	309
222	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. New England Journal of Medicine, 2015, 373, 2608-2617.	13.9	740
223	Reply. Hepatology, 2015, 62, 660-660.	3.6	9
224	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology, 2015, 61, 506-514.	3.6	424
225	The <scp>UCP</scp>2 â€866ÂG>A promoter region polymorphism is associated with nonalcoholic steatohepatitis.. Liver International, 2015, 35, 1574-1580.	1.9	41
226	O071 : Telomerase reverse transcriptase mutations are associated with hepatocellular carcinoma in nash. Journal of Hepatology, 2015, 62, S226.	1.8	1
227	P1009 : Incidence of major cardiovascular and cerebral events in patients with NAFLD and in controls of general population during 10 years of follow up: correlation between vascular and liver damage. Journal of Hepatology, 2015, 62, S725-S726.	1.8	0
228	Oxidative Stress and Hepatic Iron Overload. Oxidative Stress in Applied Basic Research and Clinical Practice, 2015, , 345-356.	0.4	2
229	PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity ,. Journal of Nutrition, 2015, 145, 1687-1691.	1.3	78
230	Cure of <scp>HCV</scp> related liver disease. Liver International, 2015, 35, 71-77.	1.9	24
231	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology, 2015, 62, 111-117.	3.6	52
232	Increased circulating adiponectin in males with chronic HCV hepatitis. European Journal of Internal Medicine, 2015, 26, 635-639.	1.0	6
233	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. DMM Disease Models and Mechanisms, 2015, 8, 1037-46.	1.2	52
234	DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis. Clinical Epigenetics, 2015, 7, 61.	1.8	83

#	Article	IF	Citations
235	Paradoxical Dissociation Between Hepatic Fat Content and De Novo Lipogenesis Due to PNPLA3 Sequence Variant. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E821-E825.	1.8	64
236	Iron Stores, Hepcidin, and Aortic Stiffness in Individuals with Hypertension. PLoS ONE, 2015, 10, e0134635.	1.1	28
237	Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors. Annals of Hepatology, 2014, 13, 568-571.	0.6	5
238	Long term changes in liver histology following treatment of chronic hepatitis C virus. Annals of Hepatology, 2014, 13, 340-349.	0.6	38
239	Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial. Hepatology International, 2014, 8, 517-526.	1.9	6
240	CDKN1A: A double-edged sword in fatty liver?. Cell Cycle, 2014, 13, 1371-1372.	1.3	8
241	Hepatic steatosis and <scp>PNPLA</scp>3 I148<scp>M</scp> variant are associated with serum <scp>F</scp>etuinâ€<scp>A</scp> independently of insulin resistance. European Journal of Clinical Investigation, 2014, 44, 627-633.	1.7	24
242	Role of iron in hepatocellular carcinoma. Clinical Liver Disease, 2014, 3, 108-110.	1.0	23
243	Reply. Hepatology, 2014, 60, 1111-1112.	3.6	0
244	Association between thePNPLA3(rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology, 2014, 59, 2170-2177.	3.6	193
245	PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Human Molecular Genetics, 2014, 23, 4077-4085.	1.4	293
246	Deciphering the Role of Ï‰3 Fatty Acids in Nonalcoholic Steatohepatitis. Journal of Pediatric Gastroenterology and Nutrition, 2014, 59, 423-424.	0.9	3
247	Genetic Insight Into the Pathogenesis of Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 139-140.	0.9	0
248	The PNPLA3 I148M variant and chronic liver disease: When a genetic mutation meets nutrients. Food Research International, 2014, 63, 239-243.	2.9	6
249	P816 MERTK rs4374383 AA GENOTYPE IS ASSOCIATED WITH A LOWER PREVALENCE OF SEVERE HEPATIC STEATOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2014, 60, S342-S343.	1.8	0
250	P271 INTERACTION BETWEEN DIETARY FACTORS AND INSULIN RESISTANCE IN THE PATHOGENESIS OF NONALCOHOLIC STEATOHEPATITIS. Journal of Hepatology, 2014, 60, S155.	1.8	0
251	P858 EPICARDIAL FAT THICKNESS IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH MARKERS OF CARDIOVASCULAR DAMAGE AND SEVERITY OF STEATOSIS. Journal of Hepatology, 2014, 60, S358.	1.8	0
252	<scp>HCV</scp> F1/F2 patients: treat now or continue to wait. Liver International, 2014, 34, 79-84.	1.9	7

#	Article	IF	Citations
253	Progression of early atherosclerotic vascular damage in patients with NAFLD and in controls of general population during 10 years of follow up. Digestive and Liver Disease, 2014, 46, e26.	0.4	0
254	Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: Effect of mono- and bi-specific somatostatin analogs on cell growth. Molecular and Cellular Endocrinology, 2014, 382, 860-870.	1.6	15
255	Hepcidin levels in chronic hemodialysis patients: a critical evaluation. Clinical Chemistry and Laboratory Medicine, 2014, 52, 613-9.	1.4	27
256	The role of interferon in the new era of hepatitis C treatments. Expert Review of Gastroenterology and Hepatology, 2014, 8, 649-656.	1.4	7
257	Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents. Genes and Nutrition, 2014, 9, 392.	1.2	56
258	P817 EARLY MENOPAUSAL STATUS IS ASSOCIATED WITH THE SEVERITY OF LIVER FIBROSIS IN ITALIAN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2014, 60, S343.	1.8	0
259	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2014, 61, 148-154.	1.8	149
260	Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2014, 46, 18-24.	0.4	9
261	My Treatment Approach to Chronic Hepatitis CÂVirus. Mayo Clinic Proceedings, 2014, 89, 934-942.	1.4	3
262	P744 DEPDC5 GENE LOCUS ASSOCIATES WITH SEVERE LIVER FIBROSIS IN INDIVIDUALS WITH CHRONIC HCV INFECTION. Journal of Hepatology, 2014, 60, S318.	1.8	1
263	A population-based study on the prevalence of NASH using scores validated against liver histology. Journal of Hepatology, 2014, 60, 839-846.	1.8	107
264	Interleukin 28B Genotype and Insulin Resistance in Chronic Hepatitis C Patients. Antiviral Therapy, 2014, 19, 747-753.	0.6	6
265	A 4â€Polymorphism Risk Score Predicts Steatohepatitis in Children With Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 632-636.	0.9	74
266	Risk of Obstructive Sleep Apnea with Daytime Sleepiness Is Associated with Liver Damage in Non-Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e96349.	1.1	31
267	Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C. PLoS ONE, 2014, 9, e106022.	1.1	9
268	A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World Journal of Gastroenterology, 2014, 20, 3002.	1.4	85
269	Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors. World Journal of Gastroenterology, 2014, 20, 12945.	1.4	117
270	Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors. Annals of Hepatology, 2014, 13, 568-71.	0.6	1

#	Article	IF	Citations
271	Dietary Iron Overload Induces Visceral Adipose Tissue Insulin Resistance. American Journal of Pathology, 2013, 182, 2254-2263.	1.9	128
272	The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. BMC Nephrology, 2013, 14, 48.	0.8	20
273	Hepatic Notch Signaling Correlates With Insulin Resistance and Nonalcoholic Fatty Liver Disease. Diabetes, 2013, 62, 4052-4062.	0.3	78
274	1373 EFFECT OF IRON DEPLETION ON LIVER DAMAGE IN NONALCOHOLIC FATTY LIVER DISEASE: PRELIMINARY RESULTS OF A RANDOMIZED CONTROLLED TRIAL. Journal of Hepatology, 2013, 58, S552-S553.	1.8	0
275	Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis. Journal of Hepatology, 2013, 58, 399-401.	1.8	14
276	A 360-degree overview of paediatric NAFLD: Recent insights. Journal of Hepatology, 2013, 58, 1218-1229.	1.8	154
277	Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects. International Journal of Obesity, 2013, 37, 986-992.	1.6	37
278	PNPLA3 I148M variant and hepatocellular carcinoma: A common genetic variant for a rare disease. Digestive and Liver Disease, 2013, 45, 619-624.	0.4	55
279	1362 RISK OF OBSTRUCTIVE SLEEP APNEA SYNDROME AND ASSOCIATION WITH LIVER DAMAGE IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE WITHOUT SEVERE OBESITY. Journal of Hepatology, 2013, 58, S547-S548.	1.8	0
280	1397 ATYPICAL JUVENILE HEMOCHROMATOSIS ASSOCIATED WITH HETEROZYGOSITY FOR NOVEL HEMOJUVELIN MUTATIONS. Journal of Hepatology, 2013, 58, S561.	1.8	1
281	399 PNPLA3 I148M AFFECTS LIVER STEATOSIS IN PATIENTS WITH CHRONIC HEPATITIS B. Journal of Hepatology, 2013, 58, S164.	1.8	1
282	104 A CANDIDATE-GENE APPROACH TO VALIDATION OF GENETIC MODIFIER ASSOCIATIONS USING A LARGE COHORT WITH HISTOLOGICALLY CHARACTERISED NON-ALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2013, 58, S46.	1.8	9
283	448 IL28B GENOTYPE IS NOT ASSOCIATED WITH INSULIN RESISTANCE IN CHRONIC HEPATITIS C PATIENTS. Journal of Hepatology, 2013, 58, S183.	1.8	0
284	Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?. Liver International, 2013, 33, 105-110.	1.9	26
285	IL28B rs12979860 polymorphism influences serum TNFalpha levels in chronic hepatitis C. Digestive and Liver Disease, 2013, 45, 348-349.	0.4	2
286	Cobalamin as a regulator of serum and cerebrospinal fluid levels of normal prions. Journal of Clinical Neuroscience, 2013, 20, 134-138.	0.8	6
287	Peroxisome Proliferator-Activated Receptor Genetic Polymorphisms and Nonalcoholic Fatty Liver Disease: Any Role in Disease Susceptibility?. PPAR Research, 2013, 2013, 1-8.	1.1	21
288	Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients. BioMed Research International, 2013, 2013, 1-6.	0.9	3

#	Article	IF	Citations
289	The I148M Variant of PNPLA3 Reduces the Response to Docosahexaenoic Acid in Children with Non-Alcoholic Fatty Liver Disease. Journal of Medicinal Food, 2013, 16, 957-960.	0.8	60
290	Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology, 2013, 58, 1245-1252.	3.6	69
291	Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment. Current Pharmaceutical Design, 2013, 19, 5219-5238.	0.9	184
292	PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2013, 8, e74089.	1.1	59
293	Dietary Anthocyanins as Nutritional Therapy for Nonalcoholic Fatty Liver Disease. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-8.	1.9	98
294	PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e75982.	1.1	42
295	PNPLA3 I148M polymorphism and progressive liver disease. World Journal of Gastroenterology, 2013, 19, 6969.	1.4	207
296	A novel alpha1-antitrypsin null variant (PiQ0Milano). World Journal of Hepatology, 2013, 5, 458.	0.8	8
297	LPIN1 rs13412852 Polymorphism in Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 588-593.	0.9	59
298	Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. International Journal of Molecular Medicine, 2012, 30, 49-56.	1.8	52
299	136 THE A736V TMPRSS6 POLYMORPHISM IS ASSOCIATED WITH THE PENETRANCE OF HEREDITARY HEMOCHROMATOSIS AND HEPATOCELLULAR CARCINOMA IN C282Y +/+ PATIENTS. Journal of Hepatology, 2012, 56, S59.	1.8	0
300	315 I148M PNPLA3 POLYMORPHISM IS ASSOCIATED WITH CLINICAL FEATURES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2012, 56, S129.	1.8	4
301	Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. Journal of Hepatology, 2012, 57, 1319-1325.	1.8	33
302	1080 LOW RATES OF SVR TO PEGINTERFERON PLUS RIBAVIRIN IN HCV GENOTYPE 1 IL28B RS12979860 CC CIRRHOTIC PATIENTS WITHOUT RAPID VIROLOGICAL RESPONSE. Journal of Hepatology, 2012, 56, S425.	1.8	0
303	The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. Journal of Hepatology, 2012, 56, 448-454.	1.8	156
304	Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. Journal of Hepatology, 2012, 56, 1209-1210.	1.8	18
305	The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterology, 2012, 12, 111.	0.8	62
306	PNPLA3 Ile148Met variant and hepatocellular carcinoma: A matter of fat. Digestive and Liver Disease, 2012, 44, 974-975.	0.4	3

#	Article	IF	Citations
307	The A736V TMPRSS6 Polymorphism Influences Hepatic Iron Overload in Nonalcoholic Fatty Liver Disease. PLoS ONE, 2012, 7, e48804.	1.1	42
308	I148M PNPLA3 variant and progressive liver disease: A new paradigm in hepatology. Hepatology, 2012, 56, 791-791.	3.6	30
309	Triple therapy for <scp>HCV</scp> genotype 1 infection: telaprevir or boceprevir?. Liver International, 2012, 32, 54-60.	1.9	24
310	Implications of <scp>PNPLA</scp>3 polymorphism in chronic hepatitis <scp>C</scp> patients receiving peginterferon plus ribavirin. Alimentary Pharmacology and Therapeutics, 2012, 35, 1434-1442.	1.9	35
311	Tâ€ARMSâ€PCR for the evaluation of rs12979860 IL28B genotype: an optimized protocol. Journal of Viral Hepatitis, 2012, 19, 228-228.	1.0	2
312	Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology, 2012, 55, 336-342.	3.6	81
313	Unraveling the genetics of fatty liver in obese children: Additive effect of P446L GCKR and I148M PNPLA3 polymorphisms. Hepatology, 2012, 55, 661-663.	3.6	37
314	IL28B, HCV core mutations, and hepatocellular carcinoma: does host genetic make-up shape viral evolution in response to immunity?. Hepatology International, 2012, 6, 356-359.	1.9	5
315	Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2012, 7, e41183.	1.1	51
316	Patatin-like phospholipase domain containing-3gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. World Journal of Gastroenterology, 2012, 18, 2813.	1.4	50
317	Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2012, 18, 3782.	1.4	43
318	Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease. World Journal of Nephrology, 2012, 1, 166.	0.8	30
319	Iron and the Adipocyte: Beware the Liver!. Immuno-gastroenterology, 2012, 1, 74.	0.4	1
320	I148M PNPLA3 variant and progressive liver disease: a new paradigm in hepatology. Hepatology, 2012, 56, 1883-9.	3.6	11
321	Interferon-Free Regimens: The Near Future, the Likely and the Not So Likely. Clinics in Liver Disease, 2011, 15, 665-675.	1.0	5
322	OC-16 Interaction between the PNPLA3 I148M mutation and body weight in determining steatosis and the progression to cirrhosis in hereditary hemochromatosis. Digestive and Liver Disease, 2011, 43, S70.	0.4	0
323	T-12 Echocardiographic epicardial fat thickness in non alcoholic fatty liver disease: A possible marker of metabolic syndrome and early vascular damage. Digestive and Liver Disease, 2011, 43, S80-S81.	0.4	2
324	F-17 Dietary iron overload induces visceral adipose tissue insulin resistance and hyper-resistinemia, and synergizes with obesity and fatty liver in inducing systemic insulin resistance. Digestive and Liver Disease, 2011, 43, S97.	0.4	1

#	Article	IF	Citations
325	Beyond hereditary hemochromatosis: New insights into the relationship between iron overload and chronic liver diseases. Digestive and Liver Disease, 2011, 43, 89-95.	0.4	69
326	1280 DIETARY IRON OVERLOAD INDUCES VISCERAL ADIPOSE TISSUE INSULIN RESISTANCE ASSOCIATED WITH HYPER-RESISTINEMIA, AND SYNERGIZES WITH OBESITY AND FATTY LIVER IN INDUCING SYSTEMIC INSULIN RESISTANCE. Journal of Hepatology, 2011, 54, S505.	1.8	6
327	Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. Journal of Hepatology, 2011, 54, 1244-1249.	1.8	107
328	Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. Journal of Hepatology, 2011, 55, 69-75.	1.8	160
329	Early interplay of intra-hepatic iron and insulin resistance in children with non-alcoholic fatty liver disease. Journal of Hepatology, 2011, 55, 647-653.	1.8	36
330	The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. Journal of Hepatology, 2011, 55, 1409-1414.	1.8	74
331	Modulation of the effect of PNPLA3 I148M mutation on steatosis and liver damage by alcohol intake in patients with chronic hepatitis C. Journal of Hepatology, 2011, 55, 1470-1471.	1.8	16
332	Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target. Journal of Hepatology, 2011, 55, 920-932.	1.8	279
333	Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 568-575.	1.1	78
334	260 ABERRANT METHYLATION OF ONCOSUPPRESSOR GENES DETECTED IN THE PERIPHERAL BLOOD OF PATIENTS WITH CHRONIC HEPATITIS C AND HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2011, 54, S107.	1.8	0
335	872 ADIPONECTIN IN NONALCOHOLIC FATTY LIVER DISEASE: CORRELATION WITH LIVER DAMAGE AND PNPLA3 GENOTYPE. Journal of Hepatology, 2011, 54, S347-S348.	1.8	1
336	903 INTERACTION BETWEEN THE PNPLA3 I148M MUTATION, BODY WEIGHT, AND STEATOSIS, IN DETERMINING THE PROGRESSION TO CIRRHOSIS IN HEREDITARY HEMOCHROMATOSIS. Journal of Hepatology, 2011, 54, S359.	1.8	0
337	A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. Journal of Viral Hepatitis, 2011, 18, 628-630.	1.0	24
338	PNPLA3 I148M polymorphism and liver damage in obese children. Journal of Pediatrics, 2011, 159, 876.	0.9	3
339	HCV Response-Guided Therapy: Should Treatment Length Be Shortened or Extended?. Current Hepatitis Reports, 2011, 10, 4-10.	0.3	5
340	Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology, 2011, 53, 791-799.	3.6	227
341	Patatin-like phospholipase domain-containing protein 3 genotype and hepatocellular carcinoma in chronic hepatitis C. Hepatology, 2011, 53, 1777-1777.	3.6	6
342	Patatin-like phospholipase domain containing-3 Ile148Met and fibrosis progression after liver transplantation. Hepatology, 2011, 54, 1484-1484.	3.6	9

#	Article	IF	Citations
343	Efficacy and Pharmacokinetics of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B and Renal Impairment. Journal of Clinical Pharmacology, 2011, 51, 1293-1301.	1.0	7
344	Serum Hepcidin and Macrophage Iron Correlate With MCP-1 Release and Vascular Damage in Patients With Metabolic Syndrome Alterations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 683-690.	1.1	78
345	Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 141-149.	0.2	64
346	Glucagon-Like Peptide 1 Inhibits the Sirtuin Deacetylase SirT1 to Stimulate Pancreatic Î²-Cell Mass Expansion. Diabetes, 2011, 60, 3217-3222.	0.3	46
347	Hemochromatosis in Italy in the last 30 years: Role of genetic and acquired factors. Hepatology, 2010, 51, 501-510.	3.6	35
348	Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology, 2010, 51, 388-397.	3.6	149
349	Hemochromatosis gene (HFE) mutations and cancer risk: Expanding the clinical manifestations of hereditary iron overload. Hepatology, 2010, 51, 1119-1121.	3.6	41
350	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology, 2010, 51, 1209-1217.	3.6	563
351	I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology, 2010, 52, 1274-1280.	3.6	252
352	Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterology, 2010, 10, 102.	0.8	53
353	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut, 2010, 59, 267-273.	6.1	148
354	Impact of Peginterferon Maintenance Therapy on the Risk of Developing Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Virus. Oncology, 2010, 78, 11-16.	0.9	7
355	A Promoter Polymorphism in the Liver-specific Fatty Acid Transport Protein 5 is Associated with Features of the Metabolic Syndrome and Steatosis. Hormone and Metabolic Research, 2010, 42, 854-859.	0.7	38
356	Serum hyaluronic acid for the screening of progressive nonalcoholic steatohepatitis in children: a promising approach. Translational Research, 2010, 156, 226-228.	2.2	3
357	HFE Genotype, Parenchymal Iron Accumulation, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2010, 138, 905-912.	0.6	246
358	Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. Journal of Hepatology, 2010, 52, 832-838.	1.8	50
359	Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2010, 53, 927-933.	1.8	60
360	Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus. Gastroenterology, 2010, 139, 120-129.e18.	0.6	633

#	Article	IF	Citations
361	14 A DRUG TRANSPORTER GENE POLYMORPHISM PREDICTS RENAL TUBULAR TOXICITY IN PATIENTS WITH CHRONIC HEPATITIS B ON LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION. Journal of Hepatology, 2010, 52, S7.	1.8	7
362	338 RISK OF EARLY ATHEROSCLEROSIS BY CAROTID ARTERY INTIMA-MEDIA THICKNESS IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE AND LOW VISCERAL ADIPOSITY. Journal of Hepatology, 2010, 52, S141.	1.8	0
363	377 BETA-GLOBIN MUTATIONS ARE ASSOCIATED WITH PARENCHYMAL SIDEROSIS AND FIBROSIS SEVERITY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2010, 52, S155-S156.	1.8	0
364	Iron-Dependent Regulation of MDM2 Influences p53 Activity and Hepatic Carcinogenesis. American Journal of Pathology, 2010, 176, 1006-1017.	1.9	68
365	127 HOMOZYGOSITY FOR THE PNPLA3/ADIPONUTRIN I148M POLYMORPHISM INFLUENCES LIVER FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2010, 52, S57.	1.8	7
366	Plasma Chromogranin A Response to Octreotide Test: Prognostic Value for Clinical Outcome in Endocrine Digestive Tumors. American Journal of Gastroenterology, 2010, 105, 2072-2078.	0.2	57
367	HFE Mutations Modulate the Effect of Iron on Serum Hepcidin-25 in Chronic Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1331-1337.	2.2	27
368	Reply:. Hepatology, 2009, 49, 697-697.	3.6	3
369	Can nonalcoholic steatohepatitis trigger porphyria cutanea tarda clinical manifestations?. Internal and Emergency Medicine, 2009, 4, 91-92.	1.0	3
370	Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporosis International, 2009, 20, 549-555.	1.3	158
371	The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?. Seminars in Immunopathology, 2009, 31, 359-369.	2.8	89
372	What future for ribavirin?. Liver International, 2009, 29, 68-73.	1.9	26
373	Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. New England Journal of Medicine, 2009, 361, 580-593.	13.9	1,166
374	Ferroportin-1 in the recurrence of hepatic iron overload after liver transplantation. Digestive and Liver Disease, 2009, 41, e17-e20.	0.4	3
375	Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial. Gastroenterology, 2009, 137, 1986-1994.	0.6	31
376	702 IRON METABOLISM ALTERATIONS ASSOCIATED WITH HEPATIC IRON ACCUMULATION IN A DIETARY MODEL OF NONALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2009, 50, S257.	1.8	0
377	726 GENOTYPE OF THE TRANSCRIPTION FACTOR FOXO1 MEDIANTING INSULIN SIGNALING INFLUENCES THE SUSCEPTIBILITY TO AND SEVERITY OF NONALCOHOLIC FATTY LIVER DISEASE BY MODULATING FOXO1 MRNA LEVELS. Journal of Hepatology, 2009, 50, S265.	1.8	0
378	Management of Hepatitis C virus Genotype 2 or 3 Infection: Treatment Optimization on the Basis of Virological Response. Antiviral Therapy, 2009, 14, 143-154.	0.6	18

#	Article	IF	Citations
379	Role and support for hepatologists at liver transplant programs in the United States. Liver Transplantation, 2008, 14, 1092-1099.	1.3	21
380	HFEmutations in nonalcoholic fatty liver disease. Hepatology, 2008, 47, 1794-1795.	3.6	11
381	Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology, 2008, 48, 792-798.	3.6	600
382	Risk of severe liver disease in nonalcoholic fatty liver disease: Role of insulin resistance. Hepatology, 2008, 48, 2088-2088.	3.6	3
383	Iron genes, dysmetabolism and fibrosis in chronic hepatitis C. Journal of Hepatology, 2008, 48, 513-514.	1.8	3
384	Carotid Artery Intima-media Thickness in Nonalcoholic Fatty Liver Disease. American Journal of Medicine, 2008, 121, 72-78.	0.6	189
385	Iron Depletion by Deferoxamine Up-Regulates Glucose Uptake and Insulin Signaling in Hepatoma Cells and in Rat Liver. American Journal of Pathology, 2008, 172, 738-747.	1.9	144
386	96 IRON DEPLETION BY DEFEROXAMINE UPREGULATES GLUCOSE UPTAKE AND INSULIN SIGNALING IN HEPATOCYTES AND IN A RAT MODEL OF FATTY LIVER. Journal of Hepatology, 2008, 48, S41.	1.8	0
387	Optimizing the Current Therapy for Chronic Hepatitis C Virus: Peginterferon and Ribavirin Dosing and the Utility of Growth Factors. Clinics in Liver Disease, 2008, 12, 487-505.	1.0	17
388	Bloodletting Ameliorates Insulin Sensitivity and Secretion in Parallel to Reducing Liver Iron in Carriers of HFE Gene Mutations: Response to Equitani et al.. Diabetes Care, 2008, 31, e18-e18.	4.3	8
389	Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis. Diabetes, 2008, 57, 1355-1362.	0.3	163
390	<i>HFE</i> Genotype Influences Erythropoiesis Support Requirement in Hemodialysis Patients: A Prospective Study. American Journal of Nephrology, 2008, 28, 311-316.	1.4	13
391	The hand arthropathy of hereditary hemochromatosis is strongly associated with iron overload. Journal of Rheumatology, 2008, 35, 153-8.	1.0	42
392	Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica, 2007, 92, 1037-1042.	1.7	66
393	A BALANCING VIEW: We Cannot Do It Alone. American Journal of Gastroenterology, 2007, 102, 1841-1843.	0.2	10
394	Iron Depletion by Phlebotomy Improves Insulin Resistance in Patients With Nonalcoholic Fatty Liver Disease and Hyperferritinemia: Evidence from a Case-Control Study. American Journal of Gastroenterology, 2007, 102, 1251-1258.	0.2	274
395	Treatment of Chronic Hepatitis C Virus in African Americans With Genotypes 2 and 3. CME. American Journal of Gastroenterology, 2007, 102, 761-766.	0.2	50
396	HFE Gene Mutations and Oxidative Stress Influence Serum Ferritin, Associated with Vascular Damage, in Hemodialysis Patients. American Journal of Nephrology, 2007, 27, 101-107.	1.4	19

#	Article	IF	Citations
397	Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3. New England Journal of Medicine, 2007, 357, 124-134.	13.9	523
398	[100] INHERITED VARIANTS OF GENES INVOLVED IN INSULIN SIGNALING AND LIPOGENESIS INFLUENCE THE RISK OF HEPATIC FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2007, 46, S44-S45.	1.8	0
399	[378] IRON STATUS MODULATES THE EXPRESSION OF THE UBIQUITIN LIGASE MDM-2 AND ITS TARGET p53 IN MOUSE HEPATOCYTES AND HUMAN MONOCYTES; EFFECT ON THE ANTI-OXIDANT RESPONSE. Journal of Hepatology, 2007, 46, S146-S147.	1.8	0
400	[709] BASELINE ALT AND FERRITIN PREDICT HISTOLOGICAL FINDINGS IN NAFLD. Journal of Hepatology, 2007, 46, S267-S268.	1.8	0
401	[710] REVISITATION OF A COHORT OF ITALIAN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS: CHANGES IN THE LAST THREE DECADES. Journal of Hepatology, 2007, 46, S268.	1.8	0
402	[769] IRON DEPLETION BY PHLEBOTOMY IMPROVES INSULIN RESISTANCE IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE AND HYPERFERRITINEMIA; EVIDENCE FROM A CASE CONTROL STUDY. Journal of Hepatology, 2007, 46, S288-S289.	1.8	0
403	[770] ROLE OF TRB3 IN THE REGULATION OF HEPATIC LIPOGENESIS IN NONALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2007, 46, S289.	1.8	0
404	Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C. Gastroenterology, 2007, 132, 103-112.	0.6	200
405	A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology, 2007, 46, 297-306.	3.6	285
406	Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology, 2007, 46, 371-379.	3.6	203
407	The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology, 2007, 46, 1091-1100.	3.6	104
408	63 Hepatic expression of the forkhead transcription factor foxO1 is increased in non-alcoholic steatohepatitis and associated with gluconeogenesis and insulin resistance. Journal of Hepatology, 2006, 44, S28-S29.	1.8	0
409	89 Risk of early atherosclerosis evaluated by carotid artery intima-media thickness in patients with non-alcoholic fatty liver disease: A case control study. Journal of Hepatology, 2006, 44, S39-S40.	1.8	3
410	Chronic Hepatitis C in Patients With Persistently Normal Alanine Transaminase Levels. Clinical Gastroenterology and Hepatology, 2006, 4, 645-652.	2.4	73
411	Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. Journal of Hepatology, 2006, 44, 679-685.	1.8	43
412	Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders. Current Gastroenterology Reports, 2006, 8, 46-52.	1.1	18
413	Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders. Current Hepatitis Reports, 2006, 5, 114-120.	0.3	0
414	Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology, 2006, 43, 682-689.	3.6	458

#	Article	IF	Citations
415	Î±1-Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage. Hepatology, 2006, 44, 857-864.	3.6	88
416	Circulating ghrelin levels in patients with inflammatory bowel disease. Gut, 2006, 55, 432-433.	6.1	46
417	Iron and insulin resistance. Alimentary Pharmacology and Therapeutics, 2005, 22, 61-63.	1.9	80
418	Nuclear Trapping of the Forkhead Transcription Factor FoxO1 via Sirt-dependent Deacetylation Promotes Expression of Glucogenetic Genes. Journal of Biological Chemistry, 2005, 280, 20589-20595.	1.6	459
419	TNFÎ± genotype affects TNFÎ± release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. Journal of Hepatology, 2005, 43, 944-950.	1.8	35
420	Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. Blood Cells, Molecules, and Diseases, 2005, 35, 27-32.	0.6	24
421	TNFÎ± Promoter Polymorphisms. , 2004, 98, 047-058.		14
422	Chronic Hepatitis C. Seminars in Liver Disease, 2004, 24, 1-2.	1.8	5
423	Treatment choices for people infected with HCV. Journal of Antimicrobial Chemotherapy, 2004, 53, 708-712.	1.3	13
424	A Balancing View: A Decision to be Shared with Patients. American Journal of Gastroenterology, 2004, 99, 975-976.	0.2	2
425	The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. Journal of Medical Genetics, 2004, 41, 946-950.	1.5	81
426	CYTOTOXIC T-LYMPHOCYTE ANTIGEN-4 A49G POLYMORPHISM IS ASSOCIATED WITH SUSCEPTIBILITY TO AND SEVERITY OF ALCOHOLIC LIVER DISEASE IN ITALIAN PATIENTS. Alcohol and Alcoholism, 2004, 39, 276-280.	0.9	27
427	Turning up the heat in the fat cell. Nature Medicine, 2004, 10, 1168-1169.	15.2	1
428	Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transplantation, 2004, 10, 1248-1255.	1.3	136
429	A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology, 2004, 2, 1107-1115.	2.4	388
430	Searching for coeliac disease in patients with non-alcoholic fatty liver disease. Digestive and Liver Disease, 2004, 36, 333-336.	0.4	76
431	Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.. Cleveland Clinic Journal of Medicine, 2004, 71, S13-S13.	0.6	6
432	Side effects of medical therapy for chronic hepatitis C. Annals of Hepatology, 2004, 3, 5-10.	0.6	11

#	Article	IF	Citations
433	Management of patients with chronic hepatitis C virus infection and previous nonresponse. Reviews in Gastroenterological Disorders, 2004, 4 Suppl 1, S22-30.	0.6	6
434	Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology, 2003, 37, 1286-1292.	3.6	984
435	Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Digestive and Liver Disease, 2003, 35, 172-178.	0.4	84
436	Correspondence. Digestive and Liver Disease, 2003, 35, 596-597.	0.4	1
437	Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance. Gastroenterology, 2003, 124, 866.	0.6	38
438	What is the contribution of differences in three measures of tumor necrosis factor-alpha activity to insulin resistance in healthy volunteers?. Metabolism: Clinical and Experimental, 2003, 52, 1593-1596.	1.5	10
439	Iron and insulin resistance: Effect of iron manipulation on insulin receptor in HEPG2 hepatocytes. Journal of Hepatology, 2003, 38, 30-31.	1.8	0
440	TNFalpha promoter polymorphisms and insulin resistance in HCV-related liver disease. Journal of Hepatology, 2003, 38, 178.	1.8	1
441	Iron overload, hfe gene mutations and insulin resistance in non alcoholic fatty liver disease (NAFLD). Digestive and Liver Disease, 2002, 34, 687.	0.4	0
442	Tumor necrosis factor Î± promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology, 2002, 122, 274-280.	0.6	285
443	Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. New England Journal of Medicine, 2002, 347, 975-982.	13.9	6,268
444	CTLA-4 recipient polymorphism influences HCV liver disease recurrence following orthotopic liver transplantation (OLT). Journal of Hepatology, 2002, 36, 43.	1.8	0
445	Cytotoxic T-lymphocyte antigen 4 is associated with development and progression of alcoholic liver disease (ALD) in Italian patients. Journal of Hepatology, 2002, 36, 66.	1.8	0
446	TNF alpha polymorphisms, HFE gene mutations and acquired factors in Italian patients with porphyria cutanea tarda. Journal of Hepatology, 2002, 36, 157-158.	1.8	58
447	Retreatment of patients with chronic hepatitis C. Hepatology, 2002, 36, S128-S134.	3.6	34
448	Retreatment of patients with chronic hepatitis C. Hepatology, 2002, 36, s128-s134.	3.6	32
449	Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology, 2001, 120, 1183-1192.	0.6	1,846
450	TNF alpha and hereditary hemocromatosis: possible interactions. Journal of Hepatology, 2001, 34, 218.	1.8	0

#	Article	IF	Citations
451	Insulin resistance and tnf alpha polymorphism in Italian patients with non alcoholic fatty liver disease (NAFLD). Journal of Hepatology, 2001, 34, 235.	1.8	1
452	Tumor necrosis factor Î± promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood, 2001, 97, 3707-3712.	0.6	88
453	A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology, 2001, 34, 395-403.	3.6	585
454	Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. American Journal of Gastroenterology, 2001, 96, 2448-2455.	0.2	207
455	Relationship between TNF-Î± and iron metabolism in differentiating human monocytic THP-1 cells. British Journal of Haematology, 2000, 110, 978-984.	1.2	52
456	Hereditary hemochromatosis in a patient with congenital dyserythropoietic anemia. Blood, 2000, 96, 3653-3655.	0.6	12
457	The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology, 1999, 30, 602-605.	3.6	24
458	Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C. New England Journal of Medicine, 1998, 339, 1485-1492.	13.9	3,341
459	Treatment of fulminant hepatic failure with intravenous prostaglandin E1. Liver Transplantation, 1998, 4, 424-431.	1.9	25
460	A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology, 1995, 22, 759-766.	3.6	209
461	The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: A conference sponsored by the national digestive diseases advisory board. Hepatology, 1995, 22, 1591-1597.	3.6	157
462	The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: A conference sponsored by the National Digestive Diseases Advisory Board. Hepatology, 1995, 22, 1591-1597.	3.6	6
463	Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. Hepatology, 1994, 19, 933-940.	3.6	66
464	Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. Hepatology, 1994, 19, 933-940.	3.6	4
465	Modulation of Iron Metabolism and Hepcidin Release by HFE Mutations in Chronic Hemodialysis Patients: Pathophysiological and Therapeutic Implications. , 0, , .		1
466	Rare Atg7 Genetic Variants Predispose to Severe Fatty Liver Disease. SSRN Electronic Journal, 0, , .	0.4	0
467	Iron overload impairs the migratory ability of a model of immature and migratory GnRH neurons. Endocrine Abstracts, 0, , .	0.0	0
468	<i>NR1H4</i> rs35724 G>C Variant Modulates Liver Damage in Nonalcoholic Fatty Liver Disease. SSRN Electronic Journal, 0, , .	0.4	0